Shares of Eli Lilly & Co. LLY rallied 2.89% to $798.89 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.78% to 6,358.91 ...

Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

What I’m thinking, as someone who owns Eli Lilly for the Charitable Trust and who wishes I owned PepsiCo, is that there might ...

As part of its long-term investment in women’s sports, Eli Lilly will be present at the WNBA All-Star Game through breast ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the company has agreed to acquire Verve Therapeutics. Eli Lilly and Company ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Eli Lilly is tagging along on actress Kym Whitley’s blockbuster summer in a fresh Zepbound partnership with the “Happy ...

Eli Lilly & Co. closed 20.16% below its 52-week high of $972.53, which the company achieved on August 22nd.

President Trump has threatened to levy tariffs of up to 200% on pharmaceutical imports. Lilly's margins could be negatively ...